The $2 billion investment will create 725 highly skilled jobs in the Holly Springs area by the end of 2028, according to the company.
The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with eight 20,000-L bioreactors with the potential to expand and add a further 24 20,000-L bioreactors based on market demand. In addition, the facility will also provide commercial scale, automated fill-finish and assembly, packaging, and labeling services. The facility is expected to be operational by spring 2025.
Holly Springs was selected for its strong pool of technical talent, local resources, and partners with the right competencies, clean energy resources, and sustainability for future growth, the company stated.
Copyright © 2021 scienceboard.net